• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Nomos and Zmed settle

Article

'Tis the season for burying the hatchet. A settlement last month by R2 and iCAD over patent infringement was followed Sept. 19 by the announcement that Nomos and Zmed had settled their differences. The radiotherapy companies put to rest two pending

'Tis the season for burying the hatchet. A settlement last month by R2 and iCAD over patent infringement was followed Sept. 19 by the announcement that Nomos and Zmed had settled their differences. The radiotherapy companies put to rest two pending patent infringement suits relating to patient positioning and target verification products, namely Nomos BAT and BAT SXi products and Zmed's SonArray product. The agreement resolves all claims and provides cross-licensing of patent rights.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.